Longitudinal Assessment of Pancreas Volume by MRI Predicts Progression to Stage 3 Type 1 Diabetes

• Published in: Diabetes care Vol. 47; no. 3; pp. 393 - 400
• Main Authors: Virostko, John, Wright, Jordan J, Williams, Jonathan M, Hilmes, Melissa A, Triolo, Taylor M, Broncucia, Hali, Du, Liping, Kang, Hakmook, Nallaparaju, Shreya, Valencia, Leah Galvez, Reyes, Demetra, Hammel, Brenna, Russell, William E, Philipson, Louis H, Waibel, Michaela, Kay, Thomas W H, Thomas, Helen E, Greeley, Siri Atma W, Steck, Andrea K, Powers, Alvin C, Moore, Daniel J
• Format: Journal Article
• Language: English
• Published: United States American Diabetes Association 01-03-2024
• Subjects: Autoantibodies; Diabetes; Diabetes mellitus (insulin dependent); Diabetes Mellitus, Type 1 - diagnosis; Glucose tolerance; Humans; Magnetic Resonance Imaging; Metabolism; Original; Pancreas; Pancreas - diagnostic imaging; Pancreas - metabolism; Prevention; Prospective Studies; Research design; Risk Factors
• ISSN: 0149-5992; 1935-5548
• DOI: 10.2337/dc23-1681

This multicenter prospective cohort study compared pancreas volume as assessed by MRI, metabolic scores derived from oral glucose tolerance testing (OGTT), and a combination of pancreas volume and metabolic scores for predicting progression to stage 3 type 1 diabetes (T1D) in individuals with multiple diabetes-related autoantibodies.
Pancreas MRI was performed in 65 multiple autoantibody-positive participants enrolled in the Type 1 Diabetes TrialNet Pathway to Prevention study. Prediction of progression to stage 3 T1D was assessed using pancreas volume index (PVI), OGTT-derived Index60 score and Diabetes Prevention Trial-Type 1 Risk Score (DPTRS), and a combination of PVI and DPTRS.
PVI, Index60, and DPTRS were all significantly different at study entry in 11 individuals who subsequently experienced progression to stage 3 T1D compared with 54 participants who did not experience progression (P < 0.005). PVI did not correlate with metabolic testing across individual study participants. PVI declined longitudinally in the 11 individuals diagnosed with stage 3 T1D, whereas Index60 and DPTRS increased. The area under the receiver operating characteristic curve for predicting progression to stage 3 from measurements at study entry was 0.76 for PVI, 0.79 for Index60, 0.79 for DPTRS, and 0.91 for PVI plus DPTRS.
These findings suggest that measures of pancreas volume and metabolism reflect distinct components of risk for developing stage 3 type 1 diabetes and that a combination of these measures may provide superior prediction than either alone.